Recently, Beijing Yiling Bio-engineering Technology Co., Ltd. (Beijing Yiling Bio), a wholly-owned subsidiary of Yiling Pharmaceutical Ltd., has successfully passed an unannounced facility inspection conducted by the U.S. Food and Drug Administration (FDA). This represents another internationally recognized quality accreditation following the company’s first FDA inspection clearance in 2022.
As the national pharmaceutical regulatory authority of the United States, the FDA is among the world’s most authoritative and influential drug regulators. Its inspection standards are rigorous, comprehensive and highly detailed, covering the full lifecycle of pharmaceuticals, including research and development, manufacturing, quality control, warehousing and distribution. Successfully passing this unannounced FDA inspection fully verifies that Beijing Yiling Bio’s integrated production and operation management system as well as full-process product quality control capabilities fully align with the most stringent global pharmaceutical benchmarks.
This FDA audit was carried out as an unannounced surprise inspection. Faced with this sudden regulatory review, Beijing Yiling Bio’s management responded promptly and coordinated overall site arrangements, with all relevant departments mobilized and coordinated without delay. Cross-functional teams including Quality, Production, Equipment & Engineering, Registration, Human Resources and Administration collaborated closely throughout the audit, strictly complying with FDA standards to support on-site verification, documentation review and process traceability. The entire inspection proceeded in an orderly, standardized and efficient manner. The inspectors spoke highly of the company’s robust, traceable quality management system and standardized on-site operation procedures. The enterprise completed formal responses to FDA Form 483 in a timely and compliant manner and received an official confirmation email from the FDA on July 2, marking the successful completion of the unannounced inspection.
Over the years, Beijing Yiling Bio has built a multidisciplinary professional team well-versed in international pharmaceutical regulations with solid hands-on operational expertise, steadily reinforcing its premium quality reputation across the global pharmaceutical supply chain. Going forward, the company will consistently uphold its core quality principle of “Compliance First, Continuous Improvement”. It will embed GMP requirements into every aspect of daily operations, internalizing standardized management philosophies and translating regulatory demands into practical on-site implementation. The company will continuously refine control workflows and strengthen execution across all operational links, striving to establish an international benchmark for pharmaceutical quality. This landmark achievement lays a solid foundation for accelerated overseas market expansion and the advancement of the brand’s comprehensive competitiveness on the global marketplace.